EGFR is also upregulated during the pathological remodeling of the lung in patients with advanced cystic fibrosis [6], while Ishii et al. found that gefitinib, an EGFR tyrosine kinase inhibitor, had a protective effect on the lung fibrosis induced by bleomycin [7]. This evidence concerns the gene EGFR and pulmonary fibrosis.